Neogenomics (NEO) Current Assets (2010 - 2026)

Neogenomics has reported Current Assets for 17 years, with the latest figure at $373.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 34.89% year-over-year to $373.7 million; the trailing twelve-month figure through Mar 2026 stood at $373.7 million (down 34.89% YoY), and the FY2025 full-year result was $376.3 million, down 36.87% from the prior year.
• Current Assets for Q1 2026 stood at $373.7 million, down from $376.3 million in the prior quarter.
• The five-year high for Current Assets was $651.1 million in Q1 2022, with the low at $373.7 million in Q1 2026.
• Historically, Current Assets has averaged $545.8 million across 5 years, with a median of $585.0 million in 2023.
• Annual changes were most pronounced in 2024 — Current Assets grew 0.56% — and 2025, when it tumbled 36.87%.
• Neogenomics' Current Assets stood at $605.3 million in 2022, then declined by 1.4% to $596.8 million in 2023, then declined by 0.13% to $596.0 million in 2024, then plunged by 36.87% to $376.3 million in 2025, then fell by 0.69% to $373.7 million in 2026.
• The last three Current Assets figures came in at $373.7 million (Q1 2026), $376.3 million (Q4 2025), and $382.5 million (Q3 2025), per Business Quant data.